News | November 11, 2024
Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Subscribe To Our Newsletter & Stay Updated
